Active Ingredient History
Levoleucovorin is the pharmacologically active isomer of leucovorin or 5-formyl tetrahydrofolic acid, a folate analog . Levoleucovorin does not require reduction by the enzyme dihydrofolate reductase in order to participate in reactions utilizing folates as a source of “onecarbon” moieties. Administration of levoleucovorin can counteract the therapeutic and toxic effects of folic acid antagonists such as methotrexate, which act by inhibiting dihydrofolate reductase. Levoleucovorin can enhance the therapeutic and toxic effects of fluoropyrimidines used in cancer therapy such as 5-fluorouracil. 5-fluorouracil is metabolized to 5-fluoro-2'-deoxyuridine-5'-monophosphate (FdUMP), which binds to and inhibits thymidylate synthase (an enzyme important in DNA repair and replication). Levoleucovorin is readily converted to another reduced folate, 5,10-methylenetetrahydrofolate, which acts to stabilize the binding of FdUMP to thymidylate synthase and thereby enhances the inhibition of this enzyme. Fusilev® (levoleucovorin) is approved by FDA for i) rescue after high-dose methotrexate therapy in osteosarcoma, ii) diminishing the toxicity and counteracting the effects of impaired methotrexate elimination and of inadvertent overdosage of folic acid antagonists and iii) in combination chemotherapy with 5-fluorouracil in the palliative treatment of patients with advanced metastatic colorectal cancer. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Adenocarcinoma (Phase 2)
Autism Spectrum Disorder (Phase 2)
Biliary Tract Neoplasms (Phase 3)
Carcinoma (Phase 3)
Carcinoma, Hepatocellular (Phase 3)
Carcinoma, Neuroendocrine (Phase 2)
Carcinoma, Non-Small-Cell Lung (Phase 1)
Carcinoma, Renal Cell (Phase 1)
Cholangiocarcinoma (Phase 3)
Chondrosarcoma (Phase 1)
Colonic Neoplasms (Phase 2)
Colorectal Neoplasms (Phase 3)
Digestive System Neoplasms (Phase 3)
Esophageal Neoplasms (Phase 3)
Gallbladder Neoplasms (Phase 3)
Gastrointestinal Neoplasms (Phase 3)
Intestinal Neoplasms (Phase 3)
Language Disorders (Phase 2)
Leukemia, Lymphocytic, Chronic, B-Cell (Phase 1)
Leukemia, Myeloid, Acute (Phase 1)
Liver Neoplasms (Phase 2)
Lymphoma, Non-Hodgkin (Phase 1)
Mutation (Phase 3)
Neoplasm Metastasis (Phase 3)
Neoplasms (Phase 3)
Pancreatic Neoplasms (Phase 3)
Proto-Oncogene Proteins B-raf (Phase 2)
Rectal Neoplasms (Phase 2)
Sarcoma (Phase 1)
Stomach Neoplasms (Phase 3)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
